Immatics, based near Munich, develops T-cell receptor (TCR) therapies and a variety of oncology product candidates, including bispecific antibodies. Its core approach uses in-house technology to generate TCRs that can recognize intracellular tumor proteins rather than cell-surface antigens targeted by CAR-Ts. TCRs can be HLA-matched, which limits use to patients with specific genetic profiles. Under a recently announced deal, Immatics will advance TCR candidates through lead-candidate validation before potential handoff. Financially, the company received a $75 million investment from Celgene as part of that partnership. No TCRs have regulatory approval today, and Immatics is positioning its pipeline toward solid-tumor indications. Immatics is a Tuebingen, Germany-based cancer immunotherapy company developing T-cell–based therapies. Its core products are adoptive cell therapies, including IMA101 (an ACTolog® endogenous T-cell therapy) and IMA201 (an ACTengine® approach using transduced exogenous T-cell receptors). The company is also developing a pipeline of bispecific TCR candidates aimed at redirecting and activating T-cell responses against tumor-specific targets. Immatics uses its XPRESIDENT® technology to identify and validate novel tumor targets for cancer immunotherapy. Led by Chairman Peter Chambré, the company is advancing multiple candidates in clinical trials and plans to continue development efforts. It recently closed a $58m Series E financing to fund those advancement efforts, with backing from dievini Hopp Biotech holding, Wellington Partners, AT Impf GmbH and Amgen. immatics biotechnologies is a clinical-stage biopharmaceutical company developing advanced immunotherapies active against cancer. Its lead product, IMA901, is in a pivotal phase 3 study in patients with renal cell carcinoma after completing a randomized phase 2 trial. The pipeline also includes IMA910, which has reported survival data in patients with advanced colorectal cancer, and IMA950, which completed a phase 1 study in patients with glioma. The company will use the recent funding to complete the current phase 3 trial with IMA901. immatics is led by CEO Paul Higham and employs approximately 80 people. The company is based in Tuebingen and Martinsried (Munich), Germany. immatics is a clinical-stage biopharmaceutical company focused on developing advanced multi-peptide cancer vaccines. Its lead candidate, IMA901, comprises 10 tumor-associated peptides (TUMAPs) found to be highly over-expressed in the majority of renal cell carcinoma (RCC) patients and is in a pivotal phase 3 trial. IMA901 holds orphan drug designation in the US and Europe for treatment of RCC in HLA-A*02 positive patients. The company raised the first €12m tranche of a planned €34m Series D to conclude development of IMA901 and complete activities necessary to prepare for regulatory filings in the US and Europe. Interim overall survival results are expected in 2014, with final data in 2015. immatics is led by CEO Paul Higham, is based in Tuebingen and Martinsried (Munich), Germany, and employs 70 people. immatics biotechnologies is a biopharmaceutical company based in Tuebingen and Munich, Germany, developing advanced therapeutic vaccines active against cancer. Its lead product, IMA901, is a rationally designed cancer vaccine comprised of 10 different tumor-associated peptides (TUMAPs) frequently over‑expressed in renal cell carcinoma (RCC). immatics plans to perform a Phase III pivotal trial of IMA901 after data that demonstrated potential overall survival benefit in patients with advanced RCC. The company is also continuing clinical development of IMA910, which is currently being evaluated in a Phase II clinical study. immatics’ pipeline has been developed using its XPRESIDENT™ technology. The new funds will be used to advance the existing pipeline. To date the company has raised more than €100m (approximately US$130m).

Total raised

$250M

Funding rounds

5

Latest round

Equity

Latest activity

Aug 2019